Phenytoin toxicity in two-month-old Thai infant with CYP2C9 gene polymorphism--A case report.

Brain Dev

Division of Neurology, Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Thailand; Division of Neurology, Department of Pediatrics, King Chulalongkorn Memorial Hospital/Thai Red Cross Society, Thailand.

Published: January 2016

Phenytoin is one of the most well established and most effective antiepileptic medications for the treatment of focal seizures. In our clinical practice, it has proven difficult to maintain therapeutic phenytoin levels in infants less than three months of age. Incidence of phenytoin toxicity in infants is very rare. The cytochrome P450 super family plays an important role in phenytoin metabolism, especially CYP2C9 and CYP2C19. In this case report, we profiled a two-month-old Thai infant who developed phenytoin toxicity resulting from CYP2C9 gene polymorphism.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.braindev.2015.05.001DOI Listing

Publication Analysis

Top Keywords

phenytoin toxicity
12
two-month-old thai
8
thai infant
8
cyp2c9 gene
8
case report
8
phenytoin
6
toxicity two-month-old
4
infant cyp2c9
4
gene polymorphism--a
4
polymorphism--a case
4

Similar Publications

Toxic-induced cerebellar syndrome (TOICS) poses substantial neurological challenges, given its diverse causes and complex manifestations. Gold nanoparticles (AuNPs) have gained significant attention owing to enhanced biocompatibility for therapeutic interventions. We aimed to investigate the impacts of AuNPs on cerebellar cytomolecular, immunohistochemical and ultrastructural alterations in the context of phenytoin-experimentally induced TOICS.

View Article and Find Full Text PDF

Phenytoin is one of the most used antiepileptic drugs. Isoniazid, a first-line antitubercular drug, blocks the CYP2C19 enzyme, preventing phenytoin from being metabolised. Concomitant use of phenytoin and isoniazid predisposes to phenytoin toxicity.

View Article and Find Full Text PDF
Article Synopsis
  • Antiseizure medications, like valproic acid (VPA), show different results in patients due to genetic factors, though there's limited research specifically on VPA compared to other drugs.
  • This study aimed to analyze how genetic variations influence the effectiveness, side effects, and serum levels of VPA in patients with genetic generalized epilepsies (GGE).
  • The results revealed that certain genetic variants are linked to treatment failure, increased serum levels, weight gain, and hair loss among GGE patients using VPA, suggesting a need for personalized medication approaches.
View Article and Find Full Text PDF

COVID-19 and severe cutaneous allergic reactions to sulfonamides.

Allergy Asthma Proc

November 2024

From the Section of Allergy, Asthma and Immunology, Department of Medicine, Pennsylvania State College of Medicine, Hershey, Pennsylvania and.

Sulfonamides are associated with severe cutaneous adverse reactions (SCARs). Coronavirus disease 2019 (COVID-19) triggers an immune response, which may increase the likelihood of developing a hypersensitivity reaction. We sought to explore the impact of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection on the probability of developing SCARs and/or erythema multiforme (EM) reactions to sulfonamides.

View Article and Find Full Text PDF

Phenytoin is a well-known anticonvulsant medication that is useful in the management of most seizure disorders. Given the narrow therapeutic index of 10-20 mg/mL, acute phenytoin overdose can occur with either oral or intravenous administration. There is no distinct antidote to phenytoin, and therefore supportive care is the treatment of choice.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!